Document is current

Any future updates will be listed below

Ruxolitinib plus Pelabresib gut wirksam

Crossref DOI link: https://doi.org/10.1007/s15004-024-0760-5

Published Online: 2024-10-16

Published Print: 2024-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark